In vitro ribosome synthesis and evolution through ribosome display

Nat Commun. 2020 Feb 28;11(1):1108. doi: 10.1038/s41467-020-14705-2.

Abstract

Directed evolution of the ribosome for expanded substrate incorporation and novel functions is challenging because the requirement of cell viability limits the mutations that can be made. Here we address this challenge by combining cell-free synthesis and assembly of translationally competent ribosomes with ribosome display to develop a fully in vitro methodology for ribosome synthesis and evolution (called RISE). We validate the RISE method by selecting active genotypes from a ~1.7 × 107 member library of ribosomal RNA (rRNA) variants, as well as identifying mutant ribosomes resistant to the antibiotic clindamycin from a library of ~4 × 103 rRNA variants. We further demonstrate the prevalence of positive epistasis in resistant genotypes, highlighting the importance of such interactions in selecting for new function. We anticipate that RISE will facilitate understanding of molecular translation and enable selection of ribosomes with altered properties.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Clindamycin / pharmacology
  • Directed Molecular Evolution
  • Drug Resistance, Bacterial / genetics
  • Epistasis, Genetic
  • Escherichia coli / drug effects
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Gene Library
  • Genotype
  • Mutation
  • Peptidyl Transferases / genetics
  • Peptidyl Transferases / metabolism
  • Protein Synthesis Inhibitors / pharmacology
  • RNA, Ribosomal / genetics
  • Ribosomal Proteins / genetics
  • Ribosomal Proteins / metabolism
  • Ribosomes / drug effects
  • Ribosomes / genetics*
  • Ribosomes / metabolism*
  • Synthetic Biology

Substances

  • Anti-Bacterial Agents
  • Protein Synthesis Inhibitors
  • RNA, Ribosomal
  • Ribosomal Proteins
  • Clindamycin
  • Peptidyl Transferases